Website maintenance is scheduled for Saturday, October 12, and Sunday, October 13. Short disruptions may occur during these days.

brand logo

Am Fam Physician. 2023;108(2):130-131

Author disclosure: No relevant financial relationships.

Details for This Review Study Population:

Adults 18 years or older with a diagnosis of symptomatic overactive bladder or detrusor overactivity

Efficacy End Points: Condition-specific quality of life; patient perception of cure or improvement; mean number of urgency episodes per 24 hours; mean number of micturitions per 24 hours

Harm End Points: Adverse events, including dry mouth and urinary retention; withdrawal from the trial due to adverse events

BenefitsHarms
1 in 7 was helped (patient perception of cure or improvement)
1 fewer episode of urgency per 24 hours on average
1 in 6 had dry mouth
1 in 111 had urinary retention
1 in 76 withdrew due to adverse events

Narrative: Overactive bladder describes a clinical syndrome of urinary urgency with or without incontinence that may be related to spontaneous contraction of the detrusor smooth muscle. Overactive bladder causes bothersome symptoms in 29.8 million U.S. adults 40 years and older, with women being affected nearly twice as often as men.1 Common treatment for overactive bladder includes oral anticholinergics, which are thought to work by blocking the muscarinic M3 receptors of the bladder's smooth muscle, causing relaxation; similar receptors are found throughout the body. Common adverse events from oral anticholinergics include dry mouth, constipation, dyspepsia, abdominal pain, urinary retention, urinary tract infection, dry eyes, blurred vision, headache, and dizziness. The Cochrane review discussed here examines the benefits and harms of anticholinergic drugs compared with placebo for the treatment of overactive bladder.2

Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Copyright ©2024 MD Aware, LLC (theNNT.com). Used with permission.

This series is coordinated by Christopher W. Bunt, MD, AFP assistant medical editor, and the NNT Group.

A collection of Medicine by the Numbers published in AFP is available at https:// www.aafp.org/afp/mbtn.

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.